Influence of allergic status and nasal polyposis on long-term Benralizumab response in eosinophilic severe asthma
Objective: It is unclear whether Benralizumab effectiveness in severe eosinophilic asthma can be influenced by nasal polyposis (NP) or allergic status associations. We evaluated whether Benralizumab long-term efficacy in asthma outcomes could be different in subjects with atopy (SAEA) compared to the effectiveness in those without allergies (SNAEA) and in individuals with NP compared to those without NP.
Methods: This observational retrospective study considered 95 consecutive patients divided into allergic (SAEA; n:65[68.4%]; skin prick tests positive [SPT] and/or IgE values ≥100 UI/mL), and non-allergic (SNAEA; n:30[31.6%], SPT negative and normal IgE levels<100 UI/mL). Overall population was also divided into two groups according to NP presence (NP+:39[41%] and NP-:56[59%]). Benralizumab treatment mean was19.7±7.2 months (range 12-35)
Le indicazioni contenute in questo sito non intendono e non devono in alcun modo sostituire il rapporto diretto tra Medico (professionisti della salute) e Paziente/lettore. È pertanto sempre opportuno consultare sempre il proprio Medico curante e/o Specialista
